Efficacy of Nilavembu Kudineer for Dengue Fever Management – An Overview of Clinical and Preclinical Evidences

Main Article Content

Naina Mohamed Pakkir Maideen

Abstract

BACKGROUND AND AIM: Dengue viral disease (DVD) is a tropical arboviral disease that is caused by dengue virus (DENV), which is transmitted mainly by the bite of female Aedes aegypti mosquitoes. No specific antiviral drug is approved yet to manage the patients with DENV infection, who are managed using symptomatic therapy and supportive care.


AIM: As a consequence, we intend to review the potential of Nilavembu kudineer in the management of DENV infection.


MATERIALS AND METHODS: To find articles pertinent to the clinical, in vitro, and in silico studies evaluating the effectiveness of Nilavembu Kudineer in the management of DENV infection, the literature was searched in databases such as Medline/PubMed Central/PubMed, Google Scholar, Science  Direct, EBSCO, Scopus, Web of science, Embase, Directory of open access journals, and reference lists.


RESULTS: Nilavembu Kudineer may be able to alleviate signs and symptoms experienced by patients with DENV infection, according to few clinical, in vitro, and in silico studies.


CONCLUSION: The  effectiveness of  Nilavembu Kudineer in  patients with  DENV  infection would  further be demonstrated by additional randomized controlled clinical trials.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Maideen NMP. Efficacy of Nilavembu Kudineer for Dengue Fever Management – An Overview of Clinical and Preclinical Evidences. SEE J Immunol [Internet]. 2023 Nov. 30 [cited 2026 Nov. 16];6(1):109-14. Available from: https://seejim.eu/index.php/seejim/article/view/6058
Section
Clinical Immunology

References

Khan MB, Yang ZS, Lin CY, Hsu MC, Urbina AN, Assavalapsakul W, et al. Dengue overview: An updated systemic review. J Infect Public Health. 2023;16(10):1625-42. https://doi.org/10.1016/j.jiph.2023.08.001 PMid: 37595484

World Health Organization. Dengue and Severe Dengue. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue [Last accessed on 2023 Sep 19].

Ajlan BA, Alafif MM, Alawi MM, Akbar NA, Aldigs EK, Madani TA. Assessment of the new World Health Organization’s dengue classification for predicting severity of illness and level of healthcare required. PLoS Negl Trop Dis. 2019;13(8):e0007144. https://doi.org/10.1371/journal.pntd.0007144 PMid: 31430283

Asish PR, Dasgupta S, Rachel G, Bagepally BS, Kumar CP. Global prevalence of asymptomatic dengue infections-a systematic review and meta-analysis. Int J Infect Dis. 2023;134:292-8. https://doi.org/10.1016/j.ijid.2023.07.010 PMid: 37463631

Kularatne SA, Dalugama C. Dengue infection: Global importance, immunopathology and management. Clin Med (Lond). 2022;22(1):9-13. https://doi.org/10.7861/clinmed.2021-0791 PMid: 35078789

Khanam A, Gutiérrez-Barbosa H, Lyke KE, Chua JV. Immune- mediated pathogenesis in dengue virus infection. Viruses. 2022;14(11):2575. https://doi.org/10.3390/v14112575 PMid: 36423184

Rathore AP, Farouk FS, John AL. Risk factors and biomarkers of severe dengue. Curr Opin Virol. 2020;43:1-8. https://doi.org/10.1016/j.coviro.2020.06.008 PMid: 32688269

Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, et al. Risk predictors of progression to severe disease during the febrile phase of dengue: A systematic review and meta-analysis. Lancet Infect Dis. 2021;21(7):1014-26. https://doi.org/10.1016/S1473-3099(20)30601-0 PMid: 33640077

Tsheten T, Clements AC, Gray DJ, Adhikary RK, Furuya- Kanamori L, Wangdi K. Clinical predictors of severe dengue: A systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):123. https://doi.org/10.1186/s40249-021-00908-2 PMid: 34627388

Rather IA, Parray HA, Lone JB, Paek WK, Lim J, Bajpai VK, et al. Prevention and control strategies to counter dengue virus infection. Front Cell Infect Microbiol. 2017;7:336. https://doi.org/10.3389/fcimb.2017.00336 PMid: 28791258

Maideen NM, Hadda TB, Almalki FA, Laarousi H, Soliman SS, Kawsar SM. Black seeds (Nigella sativa) for the management of dengue viral disease: POM analyses for the identification of new antiviral pharmacophore sites. J Med Herb. 2023;14(1):19-36. https://doi.org/10.21203/rs.3.rs-3163496/v1

Guidelines for Siddha Practitioners for Clinical Management of Dengue Fever. Central Council for Research in Siddha. Ministry of AYUSH, Government of India. Available from: https://main. ayush.gov.in/research/guidelines-for-ayush-practitioners- for-clinical-management-of-dengue [Last accessed on 2023 Sep 21].

Maideen NM. Nilavembu kudineer (siddha polyherbal decoction) for the management of COVID-19-evidences from clinical and in-silico studies: Nilavembu kudineer for COVID-19. Indian J Integr Med. 2022;2(4):85-9.

Kavinilavan R, Mekala P, Raja MJ, Arthanari Eswaran M, Thirumalaisamy G. Exploration of immunomodulatory effect of nilavembu kudineer chooranam against newcastle disease virus in backyard chicken. J Pharmacogn Phytochem. 2017;6(6):749-51.

Rubeena M, Divya KG, Sathiya RP, Sunil KK. Bioactive molecules in siddha polyherbal nilavembu kudineer alleviating symptoms of dengue/chikugunya. Tradit Med Res. 2018;3(5):215-229. https://doi.org/10.12032/tmr201813080

Mekala P, Krishna Murthy TR. Phytochemical screening and pharmacological update on kabasura kudineer choornam and nilavembu kudineer choornam. J Pharmacogn Phytochem. 2020;9(3):1031-6. https://doi.org/10.22271/phyto.2020.v9.i3q.11428

Nandini MS, Rao MR, Prabhu K, Vijayalakshmi N, Sundaram LR. The GC ms study of on siddha formulation, nilavembu kudineer (kashayam). Int J Med Res Health Sci. 2023;12(6):1-7.

Arokyaraj DM, Rathiga G. Phytochemicals and pharmacological activities of kabhasura kudineer, nilavembu kudineer, adathodai kudineer-a review. Int J Trans Res Ind Med. 2020;2(3):41-51.

Kalai Arasi R, Jeeva GR, Elangovan S, Soundararajan DK, Mubarak H, Kanakarajan A. A combination of nilavembu kudineer and adathodai manapagu in the management of dengue fever. Int J Curr Res. 2013;5(4):978-81.

Christian GJ, Subramanian M, Periyasami D, Manickavasakam K, Gunasekaran P, Sivasubramanian S, et al. Protective effect of polyherbal siddha formulation-nilavembu kudineer against common viral fevers including dengue-a case- control approach. Int J Pharm Sci Res. 2015;6(4):1656-60. https://doi.org/10.13040/ijpsr.0975-8232.6(4).1656-60

Dhanalakshmi M, Bhuvaneswari S. Clinico-hematological profile in dengue fever patients treated with papaya juice and neelavembu kudineer. Asian J Innov Res. 2016;1(1):35-41.

Chitra SM, Anbu N. Management of dengue fever by nilavembu kudineer at rggg hospital, Chennai-public health intervention through siddha system of medicine. Int J Curr Adv Res. 2019;8(11):20557-60. https://doi.org/10.24327/ijcar.2019.20560.1037

Maignana kumar R, Lavanya K, Vivek V, Ruckmani A. safety and efficacy of nilavembu kudineer in dengue fever. J Pharm Negat Results. 2022;13(7):6465-75. https://doi.org/10.47750/pnr.2022.13.S07.786

Tang LI, Ling AP, Koh RY, Chye SM, Voon KG. Screening of anti-dengue activity in methanolic extracts of medicinal plants. BMC Complement Altern Med. 2012;12(1):3. https://doi.org/10.1186/1472-6882-12-3 PMid: 22244370

Ramalingam S, Karupannan S, Padmanaban P, Vijayan S, Sheriff K, Palani G, et al. Anti-dengue activity of Andrographis paniculata extracts and quantification of dengue viral inhibition by SYBR green reverse transcription polymerase chain reaction. Ayu. 2018;39(2):87-91. https://doi.org/10.4103/ayu. ayu_144_17 PMid: 30783363

Panraksa P, Ramphan S, Khongwichit S, Smith DR. Activity of andrographolide against dengue virus. Antiviral Res 2017;139:69-78. https://doi.org/10.1016/j.antiviral.2016.12.014 PMid: 28034742

Paemanee A, Hitakarun A, Wintachai P, Roytrakul S, Smith DR. A proteomic analysis of the anti-dengue virus activity of andrographolide. Biomed Pharmacother. 2019;109:322-32. https://doi.org/10.1016/j.biopha.2018.10.054 PMid: 30396090

Kaushik S, Dar L, Kaushik S, Yadav JP. Identification and characterization of new potent inhibitors of dengue virus NS5 proteinase from Andrographis paniculata supercritical extracts on in animal cell culture and in silico approaches. J Ethnopharmacol. 2021;267:113541. https://doi.org/10.1016/j.jep.2020.113541 PMid: 33152438

Nithya P, Jeyaram C, Meenakshi Sundaram K, Chandrasekar A, Ramasamy MS. Anti-dengue viral compounds from Andrographis paniculata by in silico approach. World J Altern Med. 2014;1(2):10-16. https://doi.org/10.5829/idosi.wjam.2014.1.2.9484

Manivasagam VR, Padmini E. Inhibition studies of methyltransferase domain of dengue virus protein NS5 by a polyherbal extract-an in silico apporach. Ann Ayurvedic Med. 2020;9(2):69-84. https://doi.org/10.5455/aam.84977

Paul A, Vibhuti A, Raj VS. Evaluation of antiviral activity of Andrographis paniculata and Tinospora cordifolia using in silico and in vitro assay against DENV-2. J Pharmacogn Phytochem. 2021;10(2):486-96. https://doi.org/10.22271/phyto.2021.v10.i2f.13847

Lekshmi RK, Biju CK, Sreekumar S. Identification of potential anti-dengue lead from nilavembu through in silico study. Int J Pharm Sci Drug Res. 2021;13(5):581-8. https://doi.org/10.25004/Ijpsdr.2021.130517

Gnaneswari D, Divya D, Verma A, Shraddha S, Sharma S, Mayandi DG. Molecular docking of potential Indian medicinal plant compounds against dengue viral proteins. Indian J Tradit Knowl. 2022;21(3):537-44. https://doi.org/10.56042/ijtk.v21i3.32900

Rani AC, Sujitha S, Kalaimathi K, Vijayakumar S, Varatharaju G, Karthikeyan K, et al. Uncovering of anti-dengue molecules from plants prescribed for dengue: A computational investigation. Chem Afr. 2022;5(5):1321-36. https://doi.org/10.1007/s42250-022-00421-5

Lekha GS, Deepika E, Swetha S, Kanagarajan A, Gayathridevi V, Santhy KS. In vivo evaluation of antimicrobial, antipyretic, analgesic, and anti-inflammatory activities of nilavembu kudineer capsule in comparison with siddha classical nilavembu kudineer. Pharmacogn Res. 2020;12(4):387-93. https://doi.org/10.4103/pr.pr_23_20

Daniel AN, Mani J. Antipyretic, anti-inflammatory and analgesic properties analysis by GC-MS, FT-IR and phytochemical screening of Carica papaya (L.) and nilavembu kudineer choornam. Int J Bot Stud. 2021;6(2):392-403.

Lavanya SA, Vishva N. A study to assess the effectiveness of nilavembu kashayam on reduction of pain and fever among the community residence in selected community. Int J Res Eng Sci Manage. 2019;2(9):216-18.

Lekha GS, Kanagarajan A, Kasirajan N, Mithun, Deepa JP, Sukumar S, et al. An interventional cohort study in dengue prevalent area by using nilavembu kudineer and awareness programme. IOSR J Dent Medi Sci. 2018;17(2):19-23. https://doi.org/10.9790/0853-1702071923

World Health Organization. Dengue and Severe Dengue. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue [Last accessed on 2023 Oct 17].

World Health Organization. Global Strategy for Dengue Prevention and Control 2012-2020. Available from: https://iris.who.int/bitstream/handle/10665/75303/9789241504034_eng. pdf [Last accessed on 2023 Oct 17].

Thomas SJ, Yoon IK. A review of dengvaxia®: Development to deployment. Hum Vaccin Immunother. 2019;15(10):2295-314. https://doi.org/10.1080/21645515.2019.1658503 PMid: 31589551

Gubler DJ, Halstead SB. Is dengvaxia a useful vaccine for dengue endemic areas? BMJ. 2019;367:I5710. https://doi. org/10.1136/bmj.l5710 PMid: 31582375

Thomas SJ. Is new dengue vaccine efficacy data a relief or cause for concern?. NPJ Vaccines. 2023;8(1):55. https://doi.org/10.1038/s41541-023-00658-2 PMid: 37061527

Angelin M, Sjölin J, Kahn F, Hedberg AL, Rosdahl A, Skorup P, et al. Qdenga®-a promising dengue fever vaccine; Can it be recommended to non-immune travelers? Travel Med Infect Dis. 2023;54:102598. https://doi.org/10.1016/j.tmaid.2023.102598 PMid: 37271201

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.